

## Special Issue

# Drug Targeting Therapy in Multiple Myeloma

### Message from the Guest Editors

The prognosis of multiple myeloma has markedly improved due to the development and clinical use of novel agents, such as proteasome inhibitors, cereblon modulators, and antibodies, including anti-CD38 and anti-SLAMF7. However, it is still an incurable malignancy. Eventually, the disease will become resistant to all drugs; therefore, we must identify new therapeutic targets and develop new drugs. Several new therapeutic approaches, including bispecific antibodies connecting CD3+ T cells to the B cell maturation antigen (BCMA) or GPRC5D on myeloma cells, antibody drug conjugates (ADC), and chimeric antigen receptor T cell (CAR-T) therapy, are currently being developed. As the bcl-2 inhibitor, venetoclax, demonstrated good efficacy only against myeloma with t(11;14), developing drugs that target a specific type of myeloma is also a popular topic. Although some myeloma patients now live longer, myeloma has poor prognostic factors, such as adverse cytogenetics, extramedullary disease, and plasma cell leukemia. This Special Issue will cover not only new drugs and their targets, but also new therapeutic targets undergoing basic research exploration.

### Guest Editors

Dr. Hiroshi Handa

Department of Hematology, Gunma University Graduate School of Medicine, 3-39-22 Showa-machi, Maebashi 371-8511, Gunma, Japan

Prof. Dr. Hideto Tamura

1. Division of Diabetes, Endocrinology and Hematology, Department of Internal Medicine, Dokkyo Medical University Saitama Medical Center, Minamikoshigaya, Koshigaya-shi 343-8555, Saitama, Japan

2. Division of Hematology, Department of Medicine, Nippon Medical School, 1-1-5 Sendagi, Bunkyo-ku, Tokyo 113-0086, Japan

### Deadline for manuscript submissions

20 March 2026



## Cancers

an Open Access Journal  
by MDPI

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/176641](https://mdpi.com/si/176641)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)